Yubin Kang, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept Of Medicine, Box 3961, Durham, NC 27710
Phone (919) 668-2331
Email address yubin.kang@duke.edu

Education and Training

  • Fellow, Hematology, Oncology, Cellular Therpay, Duke University School of Medicine, 2007 - 2010
  • M.D., Shanghai Second Medical University (China), 1991

Publications

Zheng, J, Sha, Y, Roof, L, Foreman, O, Lazarchick, J, Venkta, JK, Kozlowski, C, Gasparetto, C, Chao, N, Ebens, A, Hu, J, and Kang, Y. "Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade." Cancer Letters 440-441 (October 9, 2018): 1-10.

PMID
30312729
Full Text

Sivaraj, D, Green, MM, Kang, Y, Long, GD, Rizzieri, DA, Li, Z, Garrett, AH, McIntyre, JL, Chao, NJ, and Gasparetto, C. "Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma." Blood Cancer Journal 8, no. 8 (July 31, 2018): 71-null.

PMID
30065277
Full Text

Sundaramoorthy, P, Gasparetto, C, and Kang, Y. "The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation." Cancer Medicine (May 15, 2018).

PMID
29761903
Full Text

Zheng, Z, Fan, S, Zheng, J, Huang, W, Gasparetto, C, Chao, NJ, Hu, J, and Kang, Y. "Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma." Journal of hematology & oncology 11, no. 1 (February 27, 2018): 29-.

PMID
29482577
Full Text

Kumar, SK, Callander, NS, Alsina, M, Atanackovic, D, Biermann, JS, Castillo, J, Chandler, JC, Costello, C, Faiman, M, Fung, HC, Godby, K, Hofmeister, C, Holmberg, L, Holstein, S, Huff, CA, Kang, Y, Kassim, A, Liedtke, M, Malek, E, Martin, T, Neppalli, VT, Omel, J, Raje, N, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Weber, D, Yahalom, J, Kumar, R, and Shead, DA. "NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018." Journal of the National Comprehensive Cancer Network : Jnccn 16, no. 1 (January 2018): 11-20.

PMID
29295877
Full Text

Sivaraj, D, Bacon, W, Long, GD, Rizzieri, DA, Horwitz, ME, Sullivan, KM, Kang, Y, Li, Z, Chao, NJ, and Gasparetto, C. "High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma." Bone marrow transplantation 53, no. 1 (January 2018): 34-38.

PMID
29084203
Full Text

Sung, AD, de Castro, CM, LeBlanc, TW, Long, GD, Adams, DB, Brander, DM, Dave, S, Diehl, LF, Phuong, LD, Hennig, T, Kang, Y, McKinney, MS, Rein, LAM, Sipkins, DA, Yang, Y, Chao, NJ, and Rizzieri, DA. "Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017.

Scholars@Duke

Sundaramoorthy, P, Wang, Q, Zheng, Z, Jiao, Y, Chen, BJ, Doan, PL, Chao, NJ, and Kang, Y. "Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice." Stem Cell Research & Therapy 8, no. 1 (November 15, 2017): 263-null.

PMID
29141658
Full Text

Sivaraj, D, Green, MM, Kang, Y, Rizzieri, D, Diehl, LF, Beaven, AW, Li, Z, Garrett, A, McIntyre, J, Long, GD, Chao, NJA, and Gasparetto, C. "Phase VII dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 2, 2017 - June 6, 2017.: AMER SOC CLINICAL ONCOLOGY, May 20, 2017.

Full Text

Tuchman, SA, Moore, JO, DeCastro, CD, Li, Z, Sellars, E, Kang, Y, Long, G, and Gasparetto, CG. "Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma." Journal of geriatric oncology 8, no. 3 (May 2017): 165-169.

PMID
28256432
Full Text

Pages